The Latest Breaking News from MediWound

MediWound Q1 Earnings Call Highlights

MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance its EscharEx and NexoBrid programs. On the company’s earnings call, Chief Executive Officer Ofer G

MarketBeat · May 27

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Benzinga · Aug 3, 2022

Preview: MediWound's Earnings

MediWound (NASDAQ:MDWD) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that MediWound will report an earnings per share (EPS) of $-0.11.

Benzinga · May 16, 2022